Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis

Seminars in Arthritis and Rheumatism

Volumn 31, Issue 1, 2001, Pages 4-11

  Meyer, Martin F ^a   Schnabel, Armin ^a   Schatz, Helmut ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anticardiolipin antibodies; Antiphosphatidylserine antibodies; Antiphospholipid antibodies; Lupus anticoagulant; Thrombocytopenia; Wegener's granulomatosis

Indexed keywords

CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; WEGENER GRANULOMATOSIS;

EID: 0034880669     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2001.25060     Document Type: Article

References (39)

1. Thrombocytopenia in a case of Wegener's granulomatosis
2. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides
3. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa
4. Immunology of antiphospholipid antibodies
5. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset in the lupus patients
6. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus: Possible association with thrombotic and thrombocytopenic complications
7. Diagnostik und klinische bedeutung von antiphospholipid-antikörpern
8. Antiphospholipid antibodies and syndromes
9. American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis
10. Nomenclature of systemic vasculitides. Proposal of an international consensus conference
11. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
12. Lupus anticoagulant: Clinical significance in anticardiolipin positive patients with systemic lupus erythematosus
13. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the immunogenetics of SLE
14. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: Prospective analysis of a series of 92 patients
15. IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes
16. High prevalence of thrombocytopenia in SLE patients with a high level of anticardiolipin antibodies combined with lupus anticoagulant
17. Anticardiolipin and antineutrophil antibodies in giant cell arteritis
18. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome: Correlation with thrombocytopenia and anticardiolipin antibodies
19. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome
20. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance
21. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes
22. Anticardiolipin antibodies (aCL Abs) in polymyalgia rheumatica: Giant cell arteritis (PMRGCA)
23. Late thrombotic events in patients with temporal arteritis and anticardiolipin antibodies
24. Anticardiolipin antibodies in polymyalgia rheumatica/temporal arteritis
25. Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: Association with severe vascular complications
26. Prevalence and evolution of anticardiolipin antibodies in giant cell arteritis during corticosteroid therapy. A prospective study of 20 consecutive cases
27. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: A study of 40 cases
28. Raised anticardiolipin antibodies in Takayasu's arteritis
29. Anticardiolipin antibodies: Occurrence in Behçet's syndrome
30. Negative anticardiolipin antibodies and vascular complications in Behçet's syndrome
31. Antiphospholipid and antiendothelial antibodies in Behçet's disease
32. Vasculitis associated with antiphospholipid syndrome
33. Association of lupus anticoagulant with polyarteritis nodosa: Report of a case
34. Anticardiolipin antibodies and polyarteritis nodosa
35. Recurrent cerebral infarctions in polyarteritis nodosa with circulating antiphospholipid antibodies and mitral valve disease
36. Lupus anticoagulant in anti-neutrophil cytoplasmic antibody-associated polyarteritis
37. Presence of anticardiolipin antibodies discriminates between Wegener's granulomatosis and microscopic polyarteritis
38. The role of antineutrophil cytoplasmic antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis
39. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener's granulomatosis